21 Aug 2018

ACUSON SEQUOIA ULTRASOUND COMING TO A CITY NEAR YOU

Siemens Medical Solutions USA Inc. is taking its ACUSON Sequoia Ultrasound System on the road with nine stops between Aug. 23 and Oct. 4.   Stops include: August 23: Philadelphia, The Union League August 23: Atlanta, The Westin Buckhead Atlanta August 28: Cincinnati, Hyatt Regency Cincinnati August 30: Detroit, The

0
01 Aug 2018

GE HEALTHCARE, LANTHEUS BEGIN A PHASE 3 CLINICAL TRIAL OF FLURPIRIDAZ TO TREAT CAD

GE Healthcare and Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., have started a second Phase 3 clinical trial of Flurpiridaz 18F (called the AURORA study), an investigational agent being evaluated for the detection of coronary artery disease (CAD), the most common form of heart disease.1 CAD affects an estimated

0
26 Jul 2018

STRADIS HEALTHCARE FACILITY EARNS ISO; 2 EXECS HIRED; WEBSITE REDESIGNED

  Stradis Healthcare, a provider of custom procedure trays and minor kits, has had several big events this summer, including earning ISO 13485:2016 certification for its Waukegan, Ill., facility; hiring two new executives; and overhauling its website, stradishealthcare.com. .               Stradis serves more than 1,500 surgical centers, private practices and purchasing

0
26 Jul 2018

VIEWRAY CLEANS HOUSE IN SEARCH OF GROWTH, SHAREHOLDER VALUE

ViewRay Inc., the Oakwood Village-based maker of an MRI-guided radiation therapy system called MRIdian, has named medical device industry veterans Scott Drake as president and CEO, and Shar Matin as COO, effective immediately. Both men had been executives at Spectranetics Corp., a developer and manufacturer of minimally invasive cardiovascular devices,

0
16 Jul 2018

STUDY SHOWS RESULTS CHANGING WHITE FAT INTO BROWN FAT FOR EASIER WEIGHT LOSS

Obesity results from excess white fat storage, making it difficult to treat because the effectiveness of diet, exercise, and systemic anti-obesity agents is limited, and in the latter case may cause serious side effects. As a result, researchers are investigating innovative strategies for localized delivery of fat burning compounds via

0
24 Jun 2018

INTACT VASCULAR OFFERS TOBA BTK DATA

Intact Vascular Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, has praised the publication of the Tack Optimized Balloon Angioplasty Below the Knee (TOBA BTK) clinical trial results in the current issue of Catheterization and Cardiovascular Intervention. This multi-center pilot study focused on collecting data supporting

0
21 Jun 2018

MOST VENOUS DISEASE CAN BE CLASSIFIED AS COSMETIC

      By Ronald Bush, MD, FACS In 1992, I left a busy practice of thoracic and vascular surgery and began the in-office treatment of varicose veins. At that time, high ligation and stripping using tumescent with ultra sound guided assistance was our treatment of choice for saphenous insufficiency.

0
13 Jun 2018

2018 RESEARCH SUMMIT: WORK BEGINS TO ANALYZE DATA IN RAPIDLY EXPANDING ACP PRO VENOUS REGISTRY

By Vanessa Salvia Contributing Editor Anticipation was high for many members of the phlebology community going into an April 21 closed-door research summit held alongside the International Vein Congress in Miami, convened to discuss how to make the most of the American College of Phlebology’s Patient Recorded Outcome Venous Registry,

0
07 Jun 2018

OPTALYSE PE: BTG RESULTS REINFORCE SAFETY, EFFICACY OF SHORTER, LOWER DOSE EKOS THERAPY FOR PE

BTG plc highlighted OPTALYSE PE one-year trial results, presented at the International Society on Endovascular Therapy in Florida in February. The findings confirm that bilateral pulmonary embolism (PE) patients treated in as little as two hours with a total tissue plasminogen activator (tPA) dose as low as 8mg continue to

0
29 May 2018

INTACT VASCULAR SPONSORS SYMPOSIUM ON POST-ANGIOPLASTY DISSECTIONS MAY 31

Intact Vascular Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, announced May 29 the schedule of key presentations that will be featured during a symposium sponsored together with Philips at the 19th Annual New Cardiovascular Horizons (NCVH) Conference  in New Orleans on May 31. Post-Percutaneous Transluminal Angioplasty (“PTA”)

0